{"id":492,"date":"2025-03-11T13:21:40","date_gmt":"2025-03-11T13:21:40","guid":{"rendered":"https:\/\/rttrialsqa.org.uk\/?page_id=492"},"modified":"2025-03-11T13:21:40","modified_gmt":"2025-03-11T13:21:40","slug":"hit-meso","status":"publish","type":"page","link":"https:\/\/rttrialsqa.org.uk\/?page_id=492","title":{"rendered":"HIT-MESO"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

HIT-Meso: Hemi-thoracic Irradiation with Proton Therapy in Malignant Pleural Mesothelioma<\/strong><\/h2>\n\n\n\n
Trial Summary:<\/strong><\/h5>\n\n\n\n

HIT-MESO is a Phase III randomised-controlled study to assess the impact of proton beam therapy (PBT) on patients with unilateral malignant pleural mesothelioma (MPM). The study aims to evaluate whether PBT improves progression-free survival (PFS) and overall survival (OS), while also examining its effects on quality of life and cost-effectiveness compared to standard care. The trial will recruit 148 patients across 18-20 UK sites, with randomisation into two arms. Control arm, standard active surveillance, intervention arm will receive PBT to the hemi-thorax, delivering 50Gy in 25 fractions, with an integrated boost to 60Gy for visible tumours.<\/p>\n\n\n\n

RT QA Summary:<\/strong><\/h5>\n\n\n\n

All QA activity will be streamlined with previous trial QA, where applicable. Please contact the RTTQA Group directly using the contact details below to discuss.<\/em><\/p>\n\n\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
QA Process<\/th>QA Activity<\/th>Required for Trial<\/th>Additional Details<\/th>\n<\/tr>\n<\/thead>\n
Pre-Accrual<\/td>Facility Questionnaire<\/td><\/td><\/td>\n<\/tr>\n
Outlining Benchmark Case<\/td>\"\"<\/td>1 Case<\/td>\n<\/tr>\n
Planning Benchmark Case<\/td>\"\"<\/td>1 Case<\/td>\n<\/tr>\n
Dummy Run<\/td><\/td><\/td>\n<\/tr>\n
During Accrual<\/td>Individual Case Review<\/td>\"\"<\/td>Prospective: First three cases outlining and planning
\n
\nRetrospective: Patients 4-10<\/td>\n<\/tr>\n
Data collection<\/td>\"\"<\/td>All patients<\/td>\n<\/tr>\n
Dosimetry Audit<\/td><\/td>\"\"<\/td><\/td>\n<\/tr>\n
QA Streamlining<\/td><\/td><\/td><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n

RTTQA Contact:<\/strong> enh-tr.hit-mesoqa@nhs.net<\/a><\/p>\n\n\n\n

Chief Investigator: <\/strong>Dr Crispin Hiley<\/p>\n\n\n\n

RT Lead:<\/strong> Dr David Woolf<\/p>\n\n\n\n

Sponsor:<\/strong> University College London ctc.hit-meso@ucl.ac.uk<\/a><\/p>\n\n\n\n

Funder:<\/strong> Asthma + Lung UK and Mesothelioma UK<\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

HIT-Meso: Hemi-thoracic Irradiation with Proton Therapy in Malignant Pleural Mesothelioma Trial Summary: HIT-MESO is a Phase III randomised-controlled study to assess the […]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-492","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/pages\/492","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=492"}],"version-history":[{"count":1,"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/pages\/492\/revisions"}],"predecessor-version":[{"id":494,"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/pages\/492\/revisions\/494"}],"wp:attachment":[{"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=492"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}